HORMONE THERAPY IN ADVANCED ER+/HER2- NEGATIVE BREAST CANCER WITH PI3K INHIBITORS: A REVIEW OF THE LITERATURE

HORMONE THERAPY IN ADVANCED ER+/HER2- NEGATIVE BREAST CANCER WITH PI3K INHIBITORS: A REVIEW OF THE LITERATURE

Breast cancer is a heterogenous disease, showing as several different clinical and histologic types. Most of breast cancers express hormone receptors for estrogen and progesterone, which are considered as estrogen receptor-positive and progesterone-receptor-positive, respectively. Endocrine thera...

Full description

Bibliographic Details
Main Authors:	Ivan Inkov, Desislava Penkova, George Baytchev, Zdravko Kamenov, Mila Kayriakova, Dimo Manov
Format:	Article
Language:	English
Published:	Bulgarian Association of Young Surgeons 2016-08-01
Series:	International Journal of Surgery and Medicine
Online Access:	http://dx.doi.org/10.5455/ijsm.pi3kinhibitorbreastcancer

Similar Items

BREAST DENSITY EVALUATION: A COMPARISON BETWEEN ASSESSMENT BY A RADIOLOGIST AND THE COMPUTER-ASSISTED THRESHOLD TECHNIQUE
by: George Baytchev, et al.
Published: (2015-09-01)

CONTRALATERAL PROPHYLACTIC MASTECTOMY AND SIMULTANEOUS BREAST RECONSTRUCTION WITH IMPLANTS AFTER ONE SIDED BREAST CANCER: ANALYSIS OF 12 CASES IN CONTEXT OF THE CURRENT TRENDS
by: Roman Romansky, et al.
Published: (2016-08-01)

BREAST CANCER RISK EVALUATION - A CORRELATION BETWEEN MAMMOGRAPHIC DENSITY AND THE GAIL MODEL
by: George Baytchev, et al.
Published: (2015-05-01)

The advancement and history of breast cancer surgical therapy at a glance
by: George Dimitrov, et al.
Published: (2017-04-01)

Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor–Positive, HER2-Negative Early Breast Cancer
by: Hamdy A. Azim, et al.
Published: (2016-04-01)

CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
by: Adriana Matutino, et al.
Published: (2018-12-01)

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
by: Ilenia Migliaccio, et al.
Published: (2021-05-01)

Två pi'er
by: Markovic, Miroslav
Published: (2006)

Carvacrol: An In Silico Approach of a Candidate Drug on HER2, PI3Kα, mTOR, hER-α, PR, and EGFR Receptors in the Breast Cancer
by: Oscar Herrera-Calderon, et al.
Published: (2020-01-01)

Ribociclib for the treatment of hormone-positive HER2-negative breast cancer
by: I. P. Ganshina, et al.
Published: (2019-06-01)

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women
by: Vinayak W Patil, et al.
Published: (2011-03-01)

Du er her ikke : Projektrapport
by: Bystrup, Mette Jensen
Published: (2018)

Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
by: Taobo Hu, et al.
Published: (2021-05-01)

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
by: Richard Buus, et al.
Published: (2018-09-01)

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening
by: Jangsoon Lee, et al.
Published: (2021-06-01)

Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor
by: Nick Beije, et al.
Published: (2016-11-01)

Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer
by: Pauline du Rusquec, et al.
Published: (2020-07-01)

4-H'ers learn leadership skills
Published: (1997-09-01)

Gene expression assay and Watson for Oncology for optimization of treatment in ER-positive, HER2-negative breast cancer.
by: Yun Yeong Kim, et al.
Published: (2018-01-01)

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
by: Ho Hyun Ryu, et al.
Published: (2021-05-01)

Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications
by: Claudio Vernieri, et al.
Published: (2020-04-01)

Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
by: Hanne Vos, et al.
Published: (2021-09-01)

Quantitative mast cell analysis and hormone receptor study (ER, PR and HER2/neu) in invasive carcinoma of breast
by: Rama D Pyla, et al.
Published: (2020-01-01)

A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape
by: Peiling Xie, et al.
Published: (2021-09-01)

Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”
by: Niamh M. Keegan, et al.
Published: (2021-03-01)

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
by: Gaia Griguolo, et al.
Published: (2021-02-01)

Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
by: Yang J, et al.
Published: (2020-12-01)

Multigene expression signatures in early hormone receptor positive HER 2 negative breast cancer
by: Ovcaricek Tanja, et al.
Published: (2019-09-01)

Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer
by: Samitha Andrahennadi, et al.
Published: (2021-05-01)

Dual PI3K/mTOR Inhibitor, XL765, suppresses glioblastoma growth by inducing ER stress-dependent apoptosis
by: Zhao H, et al.
Published: (2019-07-01)

Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer
by: Li Yuanyuan, et al.
Published: (2013-02-01)

The place of CDK4/6 inhibitors in real clinical practice for patients with hormone-positive HER2-negative advanced breast cancer: opinion of Moscow’s oncologists
by: L. G. Zhukova, et al.
Published: (2020-06-01)

COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer
by: Goodman Julie E, et al.
Published: (2010-11-01)

4-H'ers and Guide Dogs: Preparing for Adulthood
Published: (1981)

Camp Verde 4-H'ers Right on Target
Published: (1986)

Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor.
by: Patrizia Nanni, et al.
Published: (2012-01-01)

Palbociclib in the first line combination hormone therapy of HER2- negative metastatic hormone-dependent breast cancer. Clinical follow-up
by: M. A. Frolova, et al.
Published: (2018-07-01)

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
by: Tarah J. Ballinger, et al.
Published: (2018-08-01)

Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic mutation
by: Lee S. Schwartzberg, et al.
Published: (2021-04-01)

Integrated MicroRNA–mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer
by: Giulia Bottai, et al.
Published: (2017-01-01)